VERVE THERAPEUTICS INC (VERV) Stock News
NASDAQ:VERV - Nasdaq - US92539P1012 - Common Stock - Currency: USD
VERV Latest News, Press Relases and Analysis
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc....
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular...
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Verve Fixed Safety Concern With Gene-Editing Treatment, CEO Says
Verve Therapeutics Inc. has not seen any safety issues in a new study of its gene-editing treatment for people with high cholesterol, the company’s chief executive officer said.
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of...
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular...
Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of...
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV)....
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verve Therapeutics, Inc. ("Verve" or...
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action...
VERV Deadline: VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August...
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV)....
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of...
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verve Therapeutics, Inc. ("Verve" or...
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
Class Action Filed Against Verve Therapeutics, Inc. (VERV) - October 28, 2024 Deadline to Join - Contact The Gross Law Firm
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of...
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERV
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action...
The Gross Law Firm Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of...